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Fibroblast growth factor receptor 3 (FGFR3) is a member of the
receptor tyrosine kinase family, which is involved in embryogen-
esis, angiogenesis, and homeostasis of multiple tissues, such as
bone and lung. FGFR3 gene mutations in the germline are well-
known causes of skeletal syndromes. Interestingly, the same muta-
tions were also found as somatic mutations in various cancers
and benign skin disorders, such as multiple myeloma, cervical
carcinomas, and seborrheic keratosis (SK).
SK is one of the most common benign human skin tumors,
which originates from proliferating keratinocytes and can be found
anywhere on the skin surface with the exception of palms and
soles. Acanthosis nigricans (AN), also a benign skin tumor, shares
many similar histopathological features with SK, such as acantho-
sis, papillomatosis, hyperkeratosis, and hyperpigmentation. It has
been found in some skeletal syndromes associated with germinal
activating mutations of FGFR3, which also strongly suggested that
the occurrence of AN observed in these human disorders results
directly from the expression of mutated FGFR3 in epidermis.1 ToFigure 1 (A) The R248C mutation was the most frequent FGFR3 mutation detected in sebo
(B) the SK of patient no. 32 revealed a Y375C mutation; (C) the SK of patient no. 14 revealed
patient no. 38 revealed a K652M mutation; and (F) multiplex SnapShot reaction showed th
described in ANs so far.
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skin tumor, we screened both SKs and ANs.
After written informed consent was signed, 48SKs, 30ANs and
18 patients with normal skin (10SKs, 8ANs) as matched controls
were recruited into this study. All of the patients had no other
systemdisease. Each casewas diagnosed, based on clinical manifes-
tations and histopathological examination.
Genomic DNA was extracted from the peripheral parafﬁn-
embedded tissues using the QIAamp DNA FFPE Tissue Kit
(QIAGEN, Hilden, Germany). We screened for 11 activating muta-
tions in exon 7,10,15 of FGFR3 by the SnaPshots multiplex assay2:
c.742C>T(R248C), c.746C>G(S249C), c.1114G>T(G372C),c.1117A>
T(S373C), c.1124A>G(Y375C), c.1144G>A(G382R), c.1178C>A(A39
3E), c.1850A>G(D617G), c.1888G>A(V630M), c.1954A>G(K652E),
c.1955A>T(K652M). The assay covered all yet identiﬁed FGFR3 mu-
tations in benign acanthotic skin tumors (seborrheic keratoses,
epidermal nevi) and urothelial carcinoma.
FGFR3 mutations were found in 20 of 48 SKs (42%), while 28of
48 (58%) revealed a wild-type status at the investigated loci.
However, two ANs revealed G382R mutation of FGFR3.This is
the ﬁrst report of FGFR3 mutations in AN. These mutations
were not found in 18 matched controls (Figure 1). Five mutationsrrheic keratosis (SK) (no. 31), while normal controls showed a wild-type FGFR3 status;
a S373C mutation; (D) the SK of patient no. 7 showed a G372C mutation; (E) the SK of
e G382R mutation in patient no. 22 of acanthosis nigricans (AN), which has not been
n. Published by Elsevier Taiwan LLC. All rights reserved.
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were not found.
The FGFR3 gene contains 19 exons and encodes an extracellular
region for ligand binding composed of three immunoglobulin
(Ig)-like domains, a hydrophobic transmembrane domain and
two cytoplasmic tyrosine kinase domains. In SKs, R248C mutations
were the most frequent type of FGFR3 mutation (19%). It is a C/T
transition at a tripyrimidine site linked to UV light. R248C muta-
tions create an unpaired cysteine residue in the mutated protein.3
K652M mutations are localized in the tyrosine kinase domain.4 In
ANs, G382R is a novel mutation affecting the transmembrane
domain.5 G382R mutations also induce a shift in the FGFR3
segment that is embedded in the membrane. Although AN is a
benign skin disorder which histologically closely resembles SK,
we did not ﬁnd the same mutations in FGFR3.
In summary, we identiﬁed ﬁve reported mutations in SK and
one novel mutation in AN. Our ﬁndings provided an addition to
the FGFR3mutation database, and will contribute further to the un-
derstanding to the pathogenesis of benign skin tumors. As speciﬁc
inhibitors of FGFR3 are already available, topical treatment with
inhibitors of FGFR3 may represent a promising new non-invasive
therapy option in the treatment.
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